(INNS)
VOXALATAMAB(INND)
VOXALATAMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA/LAMBDA2, ANTI-[HOMO SAPIENS FOLH1 (FOLATE HYDROLASE, PROSTATE SPECIFIC MEMBRANE ANTIGEN, PSMA)] AND ANTI-[HOMO SAPIENS CD3E (CD3E, CD3 EPSILON)], HUMANIZED, CHIMERIC AND HOMO SAPIENS MONOCLONAL ANTIBODY, BISPECIFIC; GAMMA4 HEAVY CHAIN HUMANIZED ANTI-FOLH1 (1-451) [VH ANTI-FOLH1 (HOMO SAPIENS IGHV3-23*01 (92.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.17] (26- 33.51-58.97-113)) (1-124)-HOMO SAPIENS IGHG4*01, G4V5 H P10, G4V4 CH2 A1.3, A1.2 (CH1 (125-222), HINGE 1-12 S10>P (232) (223-234), CH2 F1.3>A (238), L1.2>A (239) (235-344), CH3 (345-449), CHS (450- 451)) (125-451)], (138-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HOMO SAPIENS ANTI-FOLH1 (1'-214') [V-KAPPA ANTI-FOLH1 (HOMO SAPIENS IGKV3-11*01 (100%) - IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89- 97)) (1'-107') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')];...; PROPOSED INN: LIST 125, RECOMMENDED INN: LIST 87(WHO)
VOXALATAMABUM(INN)